- Dirac MA, Horan KL, Doody DR, Meschke JS, Park DR, Jackson LA, Weiss NS, Winthrop KL, Cangelosi GA (2012). Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease. Am. J. Resp. Crit. Care Med., [Epub ahead of print] PMID: 22859521
- Gray SA, Weigel KM, Ali IKA, Lakey AA, Capalungan J, Domingo GJ, and Cangelosi GA (2012). Toward Low-Cost Affinity Reagents: Lyophilized Yeast-scFv Probes Specific for Pathogen Antigens. PLoS ONE, 7(2):e32042. PMID: 22363793
- Kim JH, Yeo WH, Shu ZQ, Soelberg SD, Inoue S, Kalyanasundaram D, Ludwig J, Furlong CE, Riley J, Weigel K, Cangelosi GA, Oh K, Lee KH, Gao D, and Chung JH (2012). Immunosensor toward low-cast, rapid diagnosis of tuberculosis. Lab on a Chip. 2012 Apr 21;12(8):1437-40. Epub 2012. PMID: 22395572
- Ali IK, Haque R, Siddique A, Kabir M, Sherman NE, Gray SA, Cangelosi GA, and Petri WA Jr. (2012). Proteomic analysis of the cyst stage of Entamoeba histolytica. PLoS Negl Trop Dis. 2012 May;6(5):e1643. Epub 2012 PMID: 22590659
- Cangelosi, G. A., K. M. Weigel, C. Lefthand-Begay, and J. S. Meschke. (2010). Molecular detection of viable bacterial pathogens in water by ratiometric pre-rRNA analysis. Appl. Environ. Microbiol. 76:960-962. PMID: 19948855 PMCID: PMC2812999
- Freeman R, Geier H, Weigel KM, Do J, Ford TE, and Cangelosi GA (2006). Roles for cell wall glycopeptidolipid in surface adherence and planktonic dispersal of Mycobacterium avium. Appl Environ Microbiol 72:7554-7558.
- Freeman R, Kato-Maeda M, Hauge KA, Horan KL, Oren E, Narita M, Wallis CK, Nolan C, Small PM, and Cangelosi GA (2005). Use of rapid genomic deletion typing to monitor a tuberculosis outbreak within an urban homeless population. J. Clin. Microbiol. 43:5550-5554.
Gerard A. Cangelosi, PhD
Dr. Cangelosi has worked extensively on infectious diseases, most notably in the areas of molecular diagnostics, environmental pathogens (especially detection and exposure issues), and epidemiology. His work in both public and private sectors has generated 8 patents, 2 product launches, 1 start-up company launch, and over 60 publications. These projects have addressed tuberculosis and related diseases, waterborne pathogens, enteric disease, periodontal disease, and hospital acquired infections, all of which constitute significant exposure threats in Washington and worldwide.
- Infectious disease exposure and diagnosis, focusing on mycobaterial diseases
- Understanding human exposure to tuberculosis and related diseases. Transmission and exposure are among the most poorly understood aspects of bacterial disease. Mycobacterium tuberculosis, a globally important microbial pathogen, and related environmental mycobacteria are useful models for understanding how infectious diseases emerge and spread. Molecular and epidemiological methods are being used to characterize the host, pathogen, and environmental factors involved in the acquisition of mycobacterial infections.
- Molecular detection of pathogens in environmental and clinical samples. As a method for detecting microorganisms in samples, the polymerase chain reaction (PCR) is fast, sensitive, and specific. However, its widespread use is limited by its inability to distinguish viable pathogen cells from dead cells and free nucleic acid fragments. We have shown that PCR tests for ribosomal RNA precursors (pre-rRNA) can overcome this problem. We are developing pre-rRNA tests for pathogen detection in environmental as well as clinical samples. This work is being pursued in collaboration with a commercial licensee, AttoDx, Inc.
- Improved biomarker discovery tools for infectious disease diagnosis. High-throughput methods are being developed to generate novel antibody-like "probes" for pathogen molecules in patient and environmental samples. In an NIH-funded project entitled "Accelerated Molecular Probe Pipeline," these methods are being used to identify new biomarkers of intestinal amoeba infections. The project is an international collaboration with partners in the United States, Australia, and Bangladesh.
- Tuberculosis biomarkers and diagnosis. We are working to identify biomarkers of active TB and to develop improved point-of-care tools for detecting TB biomarkers in patient samples.